Biomark Diagnostics Inc. (FRA:20B)
0.2760
0.00 (0.00%)
At close: Sep 15, 2026
Biomark Diagnostics Revenue
Biomark Diagnostics had revenue of 7.01K CAD in the quarter ending June 30, 2026, a decrease of -82.03%. This brings the company's revenue in the last twelve months to 27.80K, down -82.05% year-over-year. In the fiscal year ending March 31, 2026, Biomark Diagnostics had annual revenue of 59.79K, down -61.23%.
Revenue (ttm)
27.80K CAD
Revenue Growth
-82.05%
P/S Ratio
1,714.97
Revenue / Employee
n/a
Employees
n/a
Market Cap
29.39M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 59.79K | -94.43K | -61.23% |
| Mar 31, 2025 | 154.22K | -9.00K | -5.52% |
| Mar 31, 2024 | 163.22K | 9.73K | 6.34% |
| Mar 31, 2023 | 153.49K | 109.56K | 249.38% |
| Mar 31, 2022 | 43.93K | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Biotest GmbH & Co. KGaA | 648.90M |
| Novogenia AG | 54.30M |
| Paion AG | 14.81M |
| MagForce AG | 1.08M |
| co.don AG | 22.00K |
| bioXXmed AG | 16.73K |
| 2invest AG | -1.64M |
Biomark Diagnostics News
- 21 days ago - BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy - Newsfile Corp
- 6 weeks ago - BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day - Newsfile Corp
- 2 months ago - BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test - Newsfile Corp
- 3 months ago - BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform - Newsfile Corp
- 5 months ago - BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum - Newsfile Corp
- 8 months ago - BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology - Newsfile Corp
- 8 months ago - BioMark: 2025 Achievements & 2026 Vision - Newsfile Corp
- 8 months ago - BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors - Newsfile Corp